BPC-157 vs Thymosin beta-4
Updated 9 sources
Key differences
- 1Thymosin beta-4 works through actin and cell migration; BPC-157 through growth-factor and blood-vessel signalling.
- 2Thymosin beta-4 has Phase 2 wound and Phase 3 eye trials; BPC-157 has small case series.
Side by side
Facts from each record, in the same words as their own pages.
| BPC-157 | Thymosin beta-4 | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Forms |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
9 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study3
- He L et al. 2022, pharmacokinetics of BPC-157 in rats and dogs, Front PharmacolPubMed · checked Oct 23, 2026
- Wang X et al. 2021, NL005 Phase I full text, J Cell Mol MedPubMed Central · checked Oct 24, 2026
- Ruff D et al. 2010, IV thymosin beta4 in healthy volunteers, Ann N Y Acad SciPubMed · checked Oct 24, 2026
Regulatory4
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated April 22, 2026)FDA (Internet Archive copy) · checked Oct 24, 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · checked Oct 24, 2026
- Orphan drug designation: thymosin beta 4, neurotrophic keratopathyFDA · checked Oct 24, 2026
- Orphan drug designation: thymosin beta 4, epidermolysis bullosaFDA · checked Oct 24, 2026
Competitor guide2
- TB-500 protocol (TB-500 vs thymosin beta-4 section)peptidedosingprotocols.com · checked Oct 24, 2026
- BPC-157peptidesinsider.com · checked Oct 23, 2026